Cirevetmab

• Description :

  Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator[1].

• Product Name Alternative :

  ZTS-00521426

• UNSPSC :

  12352203

• Target :

  TGF-beta/Smad

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/cirevetmab.html

• Solubility :

  H2O

• Smiles :

  [Cirevetmab]

• References & Citations :

  [1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 35, No. 4, 2021.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported

• CAS Number :

  [2473240-98-9]